Personalis, Inc. (NASDAQ:PSNL) Stock Has Average Price Target of $14.54 According to Analysts

Shares of Personalis, Inc. (NASDAQ:PSNL) have been given an average rating of “Hold” by the eleven brokerages that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and three have given a buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $14.54.

A number of analysts have commented on PSNL shares. Lake Street Capital cut shares of Personalis from a “buy” rating to a “hold” rating and set a $16.25 target price for the company. in a report on Monday, July 20th. Craig Hallum downgraded shares of Personalis from a “buy” rating to a “hold” rating and set a $16.25 price target on the stock. in a research report on Monday, August 24th. Needham & Company LLC cut shares of Personalis from a “buy” rating to a “hold” rating in a research note on Monday, July 20th. Zacks Research raised shares of Personalis from a “strong sell” rating to a “hold” rating in a research report on Monday, September 7th. Finally, TD Cowen restated a “buy” rating on shares of Personalis in a research note on Wednesday, July 15th.

Personalis Price Performance

Shares of PSNL opened at $15.85 on Thursday. Personalis has a one year low of $4.95 and a one year high of $18.89. The firm has a market capitalization of $1.66 billion, a P/E ratio of -14.54 and a beta of 2.32. The business has a fifty day moving average of $16.30 and a 200 day moving average of $12.34.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.04). The firm had revenue of $22.36 million for the quarter, compared to analysts’ expectations of $16.69 million. Personalis had a negative net margin of 153.84% and a negative return on equity of 46.47%.

Insider Buying and Selling

In related news, CMO Richard Chen sold 3,998 shares of Personalis stock in a transaction on Friday, September 18th. The stock was sold at an average price of $16.22, for a total transaction of $64,847.56. Following the transaction, the chief marketing officer directly owned 169,882 shares in the company, valued at approximately $2,755,486.04. The trade was a 2.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Stephen Moore sold 2,068 shares of the business’s stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $16.22, for a total value of $33,542.96. Following the sale, the senior vice president directly owned 90,257 shares of the company’s stock, valued at $1,463,968.54. This represents a 2.24% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 16,456 shares of company stock valued at $266,916 over the last three months. 4.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Merck & Co. Inc. bought a new position in shares of Personalis during the 2nd quarter valued at approximately $188,202,236. BlackRock Inc. bought a new stake in Personalis during the 2nd quarter worth approximately $94,905,000. Bank of America Corp DE bought a new stake in Personalis during the 2nd quarter worth approximately $24,395,000. AIGH Capital Management LLC purchased a new position in Personalis during the second quarter valued at approximately $22,981,000. Finally, Dimensional Fund Advisors LP lifted its holdings in Personalis by 8.4% during the first quarter. Dimensional Fund Advisors LP now owns 1,066,248 shares of the company’s stock valued at $6,791,000 after purchasing an additional 83,074 shares in the last quarter. 61.91% of the stock is owned by hedge funds and other institutional investors.

About Personalis

Personalis, Inc is a genomics company focused on applying advanced sequencing and bioinformatics to cancer research and precision medicine. The company develops tests and data platforms designed to help researchers and clinicians characterize tumors, monitor disease, and support the development of targeted therapies.

Its product portfolio includes the NeXT Platform, which analyzes tumor and normal DNA and RNA to provide a detailed view of cancer biology, as well as products such as NeXT Dx, NeXT Liquid Biopsy, and NeXT Personal.